How We Do It: A Multidisciplinary Approach to 177LU DOTATATE Peptide Receptor Radionuclide Therapy

被引：23

作者：

Burkett, Brian J. ^{[1
]}

Dundar, Ayca ^{[1
]}

Young, Jason R. ^{[1
]}

Packard, Annie T. ^{[1
]}

Johnson, Geoffrey B. ^{[1
]}

Halfdanarson, Thorvardur R. ^{[2
]}

Eiring, Rachel A. ^{[2
]}

Gansen, Denise N. ^{[1
]}

Patton, Cynthia M. ^{[1
]}

Kendi, A. Tuba ^{[1
]}

机构：

[1] Mayo Clin, Dept Radiol, Div Nucl Med, 200 First St SW, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Med Oncol, 200 First St SW, Rochester, MN 55905 USA

来源：

RADIOLOGY | 2021年 / 298卷 / 02期

关键词：

RADIOLABELED SOMATOSTATIN ANALOG; ENETS CONSENSUS GUIDELINES; NEUROENDOCRINE TUMORS; NUCLEAR-MEDICINE; TYR(3) OCTREOTATE; CLINICAL UTILITY; PRRT; TOXICITY; LU-177-DOTATATE; NEOPLASMS;

D O I：

10.1148/radiol.2020201745

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Lutetium 177 (Lu-177) DOTA-0-Tyr3-Octreotate (DOTATATE) peptide receptor radionuclide therapy (PRRT) is an effective treatment for advanced gastroenteropancreatic neuroendocrine tumors. This review presents a clinical practice workflow that has been successful since Lu-177 DOTATATE PRRT was approved by the U.S. Food and Drug Administration. The workflow relies heavily on the input of a multidisciplinary team and involves a nuclear medicine consultation service, tumor board, and specific preparations in advance of therapy and day-of-therapy procedures. A systematic checklist designed to ensure appropriate selection of treatment candidates and identification of any concerns to address to safely administer PRRT is provided. All patients were evaluated with gallium 68 DOTATATE PET/CT, and in cases of high-grade tumors, they were also evaluated with fluorine 18 fluorodeoxyglucose PET/CT, with imaging findings reviewed as part of the systematic checklist before PRRT. Adverse effects are discussed and imaging follow-up regimens are reviewed, including alternative diagnostic contrast materials. Approaches to multiple challenging patient scenarios are illustrated through case examples. Finally, alternative theranostic radionuclides and treatment strategies are discussed. (C) RSNA, 2020

引用

页码：261 / 274

页数：14

共 64 条

[1] Peptide Receptor Radiotherapy Comes of Age [J].

Al-Toubah, Taymeyah ;

Strosberg, Jonathan .

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2018, 47 (03) :615-+

[2] Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors [J].

Bellizzi, Andrew M. .

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2020, 29 (02) :185-+

[3] Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors [J].

Bergsma, Hendrik ;

van Lom, Kirsten ;

Raaijmakers, Marc H. G. P. ;

Konijnenberg, M. ;

Kam, B. L. Boen L. R. ;

Teunissen, Jaap J. M. ;

de Herder, Wouter W. ;

Krenning, Eric P. ;

Kwekkeboom, Dik J. .

JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (03) :452-458

[4] Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course [J].

Bergsma, Hendrik ;

Konijnenberg, Mark W. ;

Kam, Boen L. R. ;

Teunissen, Jaap J. M. ;

Kooij, Peter P. ;

de Herder, Wouter W. ;

Franssen, Gaston J. H. ;

van Eijck, Casper H. J. ;

Krenning, Eric P. ;

Kwekkeboom, Dik J. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (03) :453-463

[5] Carcinoid heart disease [J].

Bhattacharyya, Sanjeev ;

Davar, Joseph ;

Dreyfus, Gilles ;

Caplin, Martyn E. .

CIRCULATION, 2007, 116 (24) :2860-2865

[6] PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest [J].

Bodei, Lisa ;

Kidd, Mark S. ;

Singh, Aviral ;

van der Zwan, Wouter A. ;

Severi, Stefano ;

Drozdov, Ignat A. ;

Malczewska, Anna ;

Baum, Richard P. ;

Kwekkeboom, Dik J. ;

Paganelli, Giovanni ;

Krenning, Eric P. ;

Modlin, Irvin M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (04) :895-906

[7] Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer [J].

Bodei, Lisa ;

Kwekkeboom, Dik J. ;

Kidd, Mark ;

Modlin, Irvin M. ;

Krenning, Eric P. .

SEMINARS IN NUCLEAR MEDICINE, 2016, 46 (03) :225-238

[8] Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors [J].

Bodei, Lisa ;

Kidd, Mark ;

Paganelli, Giovanni ;

Grana, Chiara M. ;

Drozdov, Ignat ;

Cremonesi, Marta ;

Lepensky, Christopher ;

Kwekkeboom, Dik J. ;

Baum, Richard P. ;

Krenning, Eric P. ;

Modlin, Irvin M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (01) :5-19

[9] Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0, Tyr3] octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors [J].

Brabander, Tessa ;

van der Zwan, Wouter A. ;

Teunissen, Jaap J. M. ;

Kam, Boen L. R. ;

Feelders, Richard A. ;

de Herder, Wouter W. ;

van Eijck, Casper H. J. ;

Franssen, Gaston J. H. ;

Krenning, Eric P. ;

Kwekkeboom, Dik J. .

CLINICAL CANCER RESEARCH, 2017, 23 (16) :4617-4624

[10] Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate [J].

Brabander, Tessa ;

van der Zwan, Wouter A. ;

Teunissen, Jaap J. M. ;

Kam, Boen L. R. ;

de herder, Wouter W. ;

Feelders, Richard A. ;

Krenning, Eric P. ;

Kwekkeboom, Dik J. .

← 1 2 3 4 5 6 7 →